Valuation
- Market cap
- 44,704,000
- Revenue TTM
- $130,000
- Net income TTM
- $-19,180,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -14,753.85%
- Debt to equity
- 0.16
Trading
- Volume
- 8,000
- Avg volume
- 68,424
- Day's range
- $1.65 – $1.76
- Shares out
- 25,400,000
- Stochastic %K
- 6%
- Beta
- 1.19
- Analysts
- Strong Sell
- Price target
- $11.33
Company profile
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigoti...
Show more
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 256 327 9630
- Website
- https://serinatherapeutics.com
- Address
- 601 Genome Way, Suite 2001, Huntsville, United States
Latest news
No headlines yet.
